Telum Therapeutics, a biotechnology company based in Navarra, Spain, has raised €18 million in a Series A round to advance its lead antimicrobial program into clinical development.
The financing was led by AMR Action Fund, with participation from new investor Inveready and follow-on backing from Invivo Partners, CDTI through SICC Innvierte, Clave Capital and Sodena.
The company is developing therapies for severe multidrug-resistant bacterial infections and will use the new funding to move its lead candidate targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii through Phase 1 trials. The capital will also support safety and translational studies, as well as broader pipeline development across Gram-negative and Gram-positive pathogens.
Telum says its discovery approach combines proprietary metagenomic datasets, synthetic biology and generative AI to identify biologically derived, protein-based antimicrobial candidates at a time when drug resistance continues to drive demand for new treatment options.
The financing was led by AMR Action Fund, with participation from new investor Inveready and follow-on backing from Invivo Partners, CDTI through SICC Innvierte, Clave Capital and Sodena.
The company is developing therapies for severe multidrug-resistant bacterial infections and will use the new funding to move its lead candidate targeting hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii through Phase 1 trials. The capital will also support safety and translational studies, as well as broader pipeline development across Gram-negative and Gram-positive pathogens.
Telum says its discovery approach combines proprietary metagenomic datasets, synthetic biology and generative AI to identify biologically derived, protein-based antimicrobial candidates at a time when drug resistance continues to drive demand for new treatment options.